BridgeBio Pharma’s Acoramidis Phase 3 trial in ATTR-CM hits primary endpoint
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company specializing in genetic diseases and cancers, announced that the Phase 3 ATTRibute-CM study of acoramidis has met its primary endpoint. Presented by Julian Gillmore at the European Society of Cardiology Congress 2023, the study confirmed the significant efficacy and safety of acoramidis for treating patients with […]